ProCE Banner Activity

Phase I Study: Dose-Adjusted TEDDI-R With Ibrutinib in Primary CNS Lymphoma

Slideset Download
Conference Coverage
Ibrutinib is active in primary CNS lymphoma, achieving clinically meaningful CSF concentrations.

Released: December 08, 2015

Expiration: December 06, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Millennium Takeda

Seagen